Zhou FH; Downton T; Freelander A; Hurwitz J; Caldon CE; Lim E, 2023, 'CDK4/6 inhibitor resistance in estrogen receptor positive breast cancer, a 2023 perspective', Frontiers in Cell and Developmental Biology, 11, pp. 1148792, http://dx.doi.org/10.3389/fcell.2023.1148792
Journal articles | 2022
Aziz D; Lee C; Chin V; Fernandez KJ; Phan Z; Waring P; Caldon CE, 2022, 'High cyclin E1 protein, but not gene amplification, is prognostic for basal-like breast cancer', Journal of Pathology: Clinical Research, 8, pp. 355 - 370, http://dx.doi.org/10.1002/cjp2.269
Journal articles | 2022
Holliday H; Yang J; Dodson E; Nikolic I; Kamili A; Wheatley M; Deng N; Alexandrou S; Davis TP; Kavallaris M; Caldon CE; McCarroll J; De Preter K; Mestdagh P; Marshall GM; Simpson KJ; Fletcher J; Swarbrick A, 2022, 'miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma', Molecular Therapy, 30, pp. 1119 - 1134, http://dx.doi.org/10.1016/j.ymthe.2022.01.004
Journal articles | 2022
Jahan Z; Benthani FA; Currey N; Parker HW; Dahlstrom JE; Caldon CE; Kohonen-Corish MRJ, 2022, 'MCC Gene Silencing Is a CpG Island Methylator Phenotype-Associated Factor That Predisposes Colon Cancer Cells to Irinotecan and Olaparib', Cancers, 14, http://dx.doi.org/10.3390/cancers14122859
Journal articles | 2021
Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Phan Z; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell DD; Serra V; Waring P; Lim E; Caldon CE, 2021, 'Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition', npj Breast Cancer, 7, http://dx.doi.org/10.1038/s41523-021-00312-x
Journal articles | 2021
Du Q; Smith GC; Luu PL; Ferguson JM; Armstrong NJ; Caldon CE; Campbell EM; Nair SS; Zotenko E; Gould CM; Buckley M; Chia KM; Portman N; Lim E; Kaczorowski D; Chan CL; Barton K; Deveson IW; Smith MA; Powell JE; Skvortsova K; Stirzaker C; Achinger-Kawecka J; Clark SJ, 2021, 'DNA methylation is required to maintain both DNA replication timing precision and 3D genome organization integrity', Cell Reports, 36, http://dx.doi.org/10.1016/j.celrep.2021.109722
Journal articles | 2021
Floerchinger A; Murphy KJ; Latham SL; Warren SC; McCulloch AT; Lee YK; Stoehr J; Mélénec P; Guaman CS; Metcalf XL; Lee V; Zaratzian A; Da Silva A; Tayao M; Rolo S; Phimmachanh M; Sultani G; McDonald L; Mason SM; Ferrari N; Ooms LM; Johnsson AKE; Spence HJ; Olson MF; Machesky LM; Sansom OJ; Morton JP; Mitchell CA; Samuel MS; Croucher DR; Welch HCE; Blyth K; Caldon CE; Herrmann D; Anderson KI; Timpson P; Nobis M, 2021, 'Optimizing metastatic-cascade-dependent Rac1 targeting in breast cancer: Guidance using optical window intravital FRET imaging', Cell Reports, 36, http://dx.doi.org/10.1016/j.celrep.2021.109689
Journal articles | 2021
Hickey TE; Selth LA; Chia KM; Laven-Law G; Milioli HH; Roden D; Jindal S; Hui M; Finlay-Schultz J; Ebrahimie E; Birrell SN; Stelloo S; Iggo R; Alexandrou S; Caldon CE; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Lim E; Carroll JS; Tilley WD, 2021, 'The androgen receptor is a tumor suppressor in estrogen receptor–positive breast cancer', Nature Medicine, 27, pp. 310 - 320, http://dx.doi.org/10.1038/s41591-020-01168-7
Journal articles | 2021
Murphy KJ; Reed DA; Vennin C; Conway JRW; Nobis M; Yin JX; Chambers CR; Pereira BA; Lee V; Filipe EC; Trpceski M; Ritchie S; Lucas MC; Warren SC; Skhinas JN; Magenau A; Metcalf XL; Stoehr J; Major G; Parkin A; Bidanel R; Lyons RJ; Zaratzian A; Tayao M; Da Silva A; Abdulkhalek L; Gill AJ; Johns AL; Biankin AV; Samra J; Grimmond SM; Chou A; Goetz JG; Samuel MS; Lyons JG; Burgess A; Caldon CE; Horvath LG; Daly RJ; Gadegaard N; Wang Y; Sansom OJ; Morton JP; Cox TR; Pajic M; Herrmann D; Timpson P, 2021, 'Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status', Science Advances, 7, http://dx.doi.org/10.1126/sciadv.abh0363
Journal articles | 2020
Achinger-Kawecka J; Valdes-Mora F; Luu PL; Giles KA; Caldon CE; Qu W; Nair S; Soto S; Locke WJ; Yeo-Teh NS; Gould CM; Du Q; Smith GC; Ramos IR; Fernandez KF; Hoon DS; Gee JMW; Stirzaker C; Clark SJ, 2020, 'Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer', Nature Communications, 11, http://dx.doi.org/10.1038/s41467-019-14098-x
Journal articles | 2020
Burgess A; Caldon CE, 2020, 'Editorial: Proceedings From ACCM19: Cell Cycle, DNA Damage Response and Telomeres', Frontiers in Cell and Developmental Biology, 8, http://dx.doi.org/10.3389/fcell.2020.00805
Journal articles | 2020
Castillo L; Young AIJ; Mawson A; Schafranek P; Steinmann AM; Nessem D; Parkin A; Johns A; Chou A; Law AMK; Lucas MC; Murphy KJ; Deng N; Gallego-Ortega D; Caldon CE; Timpson P; Pajic M; Ormandy CJ; Oakes SR, 2020, 'MCL-1 antagonism enhances the anti-invasive effects of dasatinib in pancreatic adenocarcinoma', Oncogene, 39, pp. 1821 - 1829, http://dx.doi.org/10.1038/s41388-019-1091-0
Journal articles | 2020
Du Q; Smith G; Luu PL; Ferguson J; Armstrong N; Caldon E; Campbell E; Nair S; Zotenko E; Gould C; Buckley M; Kaczorowski D; Barton K; Deveson I; Smith M; Powell J; Skvortsova K; Stirzaker C; Achinger-Kawecka J; Clark S, 2020, 'DNA methylation is required to maintain DNA replication timing precision and 3D genome integrity', , http://dx.doi.org/10.1101/2020.10.15.338855
Journal articles | 2020
Elizabeth Caldon C, 2020, 'Friends and foes: Our evolving understanding of the link between Fbxw7 and p53 in cancer', Neoplasia (United States), 22, pp. 659 - 660, http://dx.doi.org/10.1016/j.neo.2020.07.007
Lee C; Fernandez KJ; Alexandrou S; Marcelo Sergio C; Deng N; Rogers S; Burgess A; Elizabeth Caldon C, 2020, 'Cyclin E2 promotes whole genome doubling in breast cancer', Cancers, 12, pp. 1 - 19, http://dx.doi.org/10.3390/cancers12082268
Journal articles | 2020
Milioli HH; Alexandrou S; Lim E; Caldon CE, 2020, 'Cyclin E1 and cyclin E2 in ER+ breast cancer: Prospects as biomarkers and therapeutic targets', Endocrine-Related Cancer, 27, pp. R93 - R112, http://dx.doi.org/10.1530/ERC-19-0501
Journal articles | 2020
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Halilovic E; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, 2020, 'MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer', Breast Cancer Research, 22, pp. 87, http://dx.doi.org/10.1186/s13058-020-01318-2
Journal articles | 2020
Portman N; Milioli HH; Alexandrou S; Coulson R; Yong A; Fernandez KJ; Chia KM; Segara D; Parker A; Haupt S; Haupt Y; Tilley WD; Swarbrick A; Caldon CE; Lim E, 2020, 'MDM2 Inhibition in Combination with Endocrine Therapy and CDK4/6 Inhibition for the Treatment of ER-Positive Breast Cancer', , http://dx.doi.org/10.1101/2020.06.09.140921
Journal articles | 2020
Tadesse S; Anshabo AT; Portman N; Lim E; Tilley W; Caldon CE; Wang S, 2020, 'Targeting CDK2 in cancer: challenges and opportunities for therapy', Drug Discovery Today, 25, pp. 406 - 413, http://dx.doi.org/10.1016/j.drudis.2019.12.001
Journal articles | 2019
Alexandrou S; George SM; Ormandy CJ; Lim E; Oakes SR; Elizabeth Caldon C, 2019, 'The proliferative and apoptotic landscape of basal-like breast cancer', International Journal of Molecular Sciences, 20, http://dx.doi.org/10.3390/ijms20030667
Journal articles | 2019
Aziz D; Lee C; Chin V; Fernandez K; Etemadmoghadam D; Bowtell D; Waring PM; Caldon CE, 2019, 'Cyclin E1 is a shared biomarker of subsets of high grade serous ovarian cancer (HGSOC) and basal like breast cancer (BLBC)', Annals of Oncology, 30, pp. ix86 - ix86, http://dx.doi.org/10.1093/annonc/mdz426.029
Journal articles | 2019
Caldon CE; Burgess A, 2019, 'Label free, quantitative single-cell fate tracking of time-lapse movies', MethodsX, 6, pp. 2468 - 2475, http://dx.doi.org/10.1016/j.mex.2019.10.014
Journal articles | 2019
Chia KM; Milioli H; Portman N; Laven-Law G; Coulson R; Yong A; Segara D; Parker A; Caldon CE; Deng N; Swarbrick A; Tilley WD; Hickey TE; Lim E, 2019, 'Non-canonical AR activity facilitates endocrine resistance in breast cancer', Endocrine-Related Cancer, 26, pp. 251 - 264, http://dx.doi.org/10.1530/ERC-18-0333
Journal articles | 2019
Currey N; Jahan Z; Caldon CE; Tran PN; Benthani F; De Lacavalerie P; Roden DL; Gloss BS; Campos C; Bean EG; Bullman A; Reibe-Pal S; Dinger ME; Febbraio MA; Clarke SJ; Dahlstrom JE; Kohonen-Corish MRJ, 2019, 'Mouse Model of Mutated in Colorectal Cancer Gene Deletion Reveals Novel Pathways in Inflammation and Cancer', Cellular and Molecular Gastroenterology and Hepatology, 7, pp. 819 - 839, http://dx.doi.org/10.1016/j.jcmgh.2019.01.009
Journal articles | 2019
Du Q; Bert SA; Armstrong NJ; Caldon CE; Song JZ; Nair SS; Gould CM; Luu PL; Peters T; Khoury A; Qu W; Zotenko E; Stirzaker C; Clark SJ, 2019, 'Replication timing and epigenome remodelling are associated with the nature of chromosomal rearrangements in cancer', Nature Communications, 10, pp. 416, http://dx.doi.org/10.1038/s41467-019-08302-1
Lee CS; Rogers S; Fernandez K; Alexandrou S; Deng N; Sergio CM; Kulkarni A; Gugasyan L; Musgrove EA; Deans AJ; Burgess A; Caldon CE, 2019, 'Mechanisms underlying uncontrolled genome doubling in breast cancer', Oncology Abstracts, http://dx.doi.org/10.1530/oncolabs.1.p008
Journal articles | 2019
Li A; Geyer FC; Blecua P; Lee JY; Selenica P; Brown DN; Pareja F; Lee SSK; Kumar R; Rivera B; Bi R; Piscuoglio S; Wen HY; Lozada JR; Gularte-Mérida R; Cavallone L; Aghmesheh M; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Blackburn A; Bogwitz M; Brown M; Burgess M; Burke J; Butow P; Caldon L; Campbell I; Christian A; Clarke C; Cohen P; Crook A; Cui J; Cummings M; Dawson SJ; De Fazio A; Delatycki M; Dobrovic A; Dudding T; Duijf P; Edkins E; Edwards S; Farshid G; Fellows A; Field M; Flanagan J; Fong P; Forbes J; Forrest L; Fox S; French J; Friedlander M; Ortega DG; Gattas M; Giles G; Gill G; Gleeson M; Greening S; Haan E; Harris M; Hayward N; Hickie I; Hopper J; Hunt C; James P; Jenkins M; Kefford R; Kentwell M; Kirk J; Kollias J; Lakhani S; Lindeman G; Lipton L; Lobb L; Lok S; Macrea F; Mann G; Marsh D; McLachlan SA; Meiser B; Milne R; Nightingale S; O’Connell S; Pachter N; Patterson B; Phillips K; Saleh M; Salisbury E; Saunders C; Saunus J; Scott C; Scott R; Sexton A; Shelling A; Simpson P; Spigelman A; Spurdle M; Stone J, 2019, 'Homologous recombination DNA repair defects in PALB2-associated breast cancers', npj Breast Cancer, 5, http://dx.doi.org/10.1038/s41523-019-0115-9
Journal articles | 2019
Portman N; Alexandrou S; Carson E; Wang S; Lim E; Caldon CE, 2019, 'Overcoming CDK4/6 inhibitor resistance in ER-positive breast cancer', Endocrine-Related Cancer, 26, pp. R15 - R30, http://dx.doi.org/10.1530/ERC-18-0317
Journal articles | 2019
Tadesse S; Caldon EC; Tilley W; Wang S, 2019, 'Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update', Journal of Medicinal Chemistry, 62, pp. 4233 - 4251, http://dx.doi.org/10.1021/acs.jmedchem.8b01469
Journal articles | 2018
Aziz D; Etemadmoghadam D; Caldon CE; Au-Yeung G; Deng N; Hutchinson R; Bowtell D; Waring P, 2018, '19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes', Gynecologic Oncology, 151, pp. 327 - 336, http://dx.doi.org/10.1016/j.ygyno.2018.08.039
Journal articles | 2018
Conway JRW; Warren SC; Herrmann D; Murphy KJ; Cazet AS; Vennin C; Shearer RF; Killen MJ; Magenau A; Mélénec P; Pinese M; Nobis M; Zaratzian A; Boulghourjian A; Da Silva AM; del Monte-Nieto G; Adam ASA; Harvey RP; Haigh JJ; Wang Y; Croucher DR; Sansom OJ; Pajic M; Caldon CE; Morton JP; Timpson P, 2018, 'Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer', Cell Reports, 23, pp. 3312 - 3326, http://dx.doi.org/10.1016/j.celrep.2018.05.038
Journal articles | 2018
Rogers S; McCloy RA; Parker BL; Gallego-Ortega D; Law AMK; Chin VT; Conway JRW; Fey D; Millar EKA; O’Toole S; Deng N; Swarbrick A; Chastain PD; Cesare AJ; Timpson P; Caldon CE; Croucher DR; James DE; Watkins DN; Burgess A, 2018, 'MASTL overexpression promotes chromosome instability and metastasis in breast cancer', Oncogene, 37, pp. 4518 - 4533, http://dx.doi.org/10.1038/s41388-018-0295-z
Journal articles | 2017
Law AMK; Yin JXM; Castillo L; Young AIJ; Piggin C; Rogers S; Caldon CE; Burgess A; Millar EKA; O'Toole SA; Gallego-Ortega D; Ormandy CJ; Oakes SR, 2017, 'Andy's Algorithms: New automated digital image analysis pipelines for FIJI', Scientific Reports, 7, http://dx.doi.org/10.1038/s41598-017-15885-6
Rogers S; Fey D; McCloy RA; Parker BL; Mitchell NJ; Payne RJ; Daly RJ; James DE; Caldon CE; Watkins DN; Croucher DR; Burgess A, 2016, 'PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells', Journal of Cell Science, 129, pp. 1340 - 1354, http://dx.doi.org/10.1242/jcs.179754
Journal articles | 2015
Loh SF; Cooper C; Selinger CI; Barnes EH; Chan C; Carmalt H; West R; Gluch L; Beith JM; Caldon CE; O'Toole S, 2015, 'Cell cycle marker expression in benign and malignant intraductal papillary lesions of the breast', Journal of Clinical Pathology, 68, pp. 187 - 191, http://dx.doi.org/10.1136/jclinpath-2014-202331
Journal articles | 2015
Rogers S; Gloss BS; Lee CS; Sergio CM; Dinger ME; Musgrove EA; Burgess A; Caldon CE, 2015, 'Cyclin E2 is the predominant E-cyclin associated with NPAT in breast cancer cells', Cell Division, 10, http://dx.doi.org/10.1186/s13008-015-0007-9
Journal articles | 2015
Susanto JM; Colvin EK; Pinese M; Chang DK; Pajic M; Mawson A; Caldon CE; Musgrove EA; Henshall SM; Sutherland RL; Biankin AV; Scarlett CJ, 2015, 'The epigenetic agents suberoylanilide hydroxamic acid and 5-AZA-2′ deoxycytidine decrease cell proliferation, induce cell death and delay the growth of MiaPaCa2 pancreatic cancer cells in vivo', International Journal of Oncology, 46, pp. 2223 - 2230, http://dx.doi.org/10.3892/ijo.2015.2894
Journal articles | 2014
Caldon CE, 2014, 'Estrogen signaling and the dna damage response in hormone dependent breast cancers', Frontiers in Oncology, 4 MAY, http://dx.doi.org/10.3389/fonc.2014.00106
Journal articles | 2014
McCloy RA; Rogers S; Caldon CE; Lorca T; Castro A; Burgess A, 2014, 'Partial inhibition of Cdk1 in G2 phase overrides the SAC and decouples mitotic events', Cell Cycle, 13, pp. 1400 - 1412, http://dx.doi.org/10.4161/cc.28401
Stone A; Cowley MJ; Valdes-Mora F; McCloy RA; Sergio CM; Gallego-Ortega D; Caldon CE; Ormandy CJ; Biankin AV; Gee JMW; Nicholson RI; Print CG; Clark SJ; Musgrove EA, 2013, 'BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer', Molecular Cancer Therapeutics, 12, pp. 1874 - 1885, http://dx.doi.org/10.1158/1535-7163.MCT-13-0012
Journal articles | 2012
Caldon CE; Sergio CM; Kang J; Muthukaruppan A; Boersma MN; Stone A; Barraclough J; Lee CS; Black MA; Miller LD; Gee JM; Nicholson RI; Sutherland RL; Print CG; Musgrove EA, 2012, 'Cyclin E2 Overexpression Is Associated with Endocrine Resistance but not Insensitivity to CDK2 Inhibition in Human Breast Cancer Cells', MOLECULAR CANCER THERAPEUTICS, 11, pp. 1488 - 1499, http://dx.doi.org/10.1158/1535-7163.MCT-11-0963
Journal articles | 2012
Caldon CE; Sergio CM; Kang JW; Muthukaruppan A; Boersma M; Stone A; Barraclough J; Lee CS; Black MJ; Miller LA; Gee JMW; Robert i nicholson RI; Sutherland RL; Print C; Musgrove EA, 2012, 'Cyclin E2 overexpression is associated with endocrine resistance but not insensivity to CDK2 inhibition in human breast cancer cells', Molecular Cancer Therapeutics, 11, pp. 1488 - 1499, http://dx.doi.org/10.1158/1535-7163.MCT-11-0963
Journal articles | 2012
Kalyuga M; Gallego-Ortega D; Lee H; Roden DL; Cowley MJ; Caldon CE; Stone A; Allerdice SL; Valdes-Mora F; Rosalind launchbury R; Statham A; Armstrong NJ; Alles MC; Adelaide young A; Egger A; Au W; Piggin CL; Evans C; Ledger A; Brummer T; Oakes SR; Kaplan W; Gee JMW; Robert i nicholson RI; Sutherland RL; Swarbrick A; Naylor MJ; Clark SJ; Carroll JS; Ormandy CJ, 2012, 'ELF5 Suppresses Estrogen Sensitivity and Underpins the Acquisition of Antiestrogen Resistance in Luminal Breast Cancer', PLoS Biology, 10, pp. e1001461, http://dx.doi.org/10.1371/journal.pbio.1001461
Journal articles | 2011
Musgrove EA; Caldon CE; Barraclough J; Stone A; Sutherland RL, 2011, 'Cyclin D as a therapeutic target in cancer', Nature Reviews Cancer, 11, pp. 558 - 572, http://dx.doi.org/10.1038/nrc3090
Journal articles | 2009
Caldon CE; Sergio CM; Schutte J; Boersma M; Sutherland RL; Carroll J; Musgrove EA, 2009, 'Estrogen regulation of cyclin E2 requires cyclin D1 but not c-Myc', Molecular and Cellular Biology, 29, pp. 4623 - 4639, http://dx.doi.org/10.1128/MCB.00269-09
Journal articles | 2008
Butt A; Caldon CE; Mcneil CM; Swarbrick A; Musgrove EA; Sutherland RL, 2008, 'Cell cycle machinery: Links with genesis and treatment of breast cancer', Advances in Experimental Medicine and Biology, 630, pp. 189 - 205, http://dx.doi.org/10.1007/978-0-387-78818-0_12
Journal articles | 2008
Caldon CE; Lee CS; Sutherland RL; Musgrove EA, 2008, 'Wilms` tumor protein 1: an early target of progestin regulation in T-47D breast cancer cells that modulates proliferation and differentiation', Oncogene, 27, pp. 126 - 138, http://dx.doi.org/10.1038/sj.onc.1210622
Journal articles | 2008
Caldon CE; Swarbrick A; Lee CS; Sutherland RL; Musgrove EA, 2008, 'The helix-loop-helix protein Id1 requires cyclin D1 to promote the proliferation of mammary epithelial cell acini', Cancer research, 68, pp. 3026 - 3036, http://dx.doi.org/10.1158/0008-5472.CAN-07-3079
Journal articles | 2008
Musgrove EA; Sergio CM; Loi S; Inman CK; Anderson LR; Alles MC; Pinese M; Caldon CE; Schutte J; Gardiner-Garden M; Ormandy CJ; McArthur G; Butt A; Sutherland RL, 2008, 'Identification of functional networks of estrogen-and c-Myc-responsive genes and their relationship to response to tamoxifen therapy in breast cancer', PLoS One, 3, pp. 2987 - 2995, http://dx.doi.org/10.1371/journal.pone.0002987
Journal articles | 2006
Brummer T; Schramek D; Hayes V; Bennett HL; Caldon CE; Musgrove EA; Daly RJ, 2006, 'Increased proliferation and altered growth factor dependence of human mammary epithelial cells overexpressing the Gab2 docking protein', The Journal of Biological Chemistry, 281, pp. 626 - 637, http://dx.doi.org/10.1074/jbc.M509567200
Journal articles | 2006
Caldon CE; Daly RJ; Sutherland RL; Musgrove EA, 2006, 'Cell cycle control in breast cancer cells', Journal of Cellular Biochemistry, 97, pp. 261 - 274, http://dx.doi.org/10.1002/jcb.20690
Journal articles | 2005
Swarbrick A; Akerfeldt M; Lee CS; Sergio CM; Caldon CE; Hunter LJ; Sutherland RL; Musgrove EA; Lee CS, 2005, 'Regulation of cyclin expression and cell cycle progression in breastepithelial cells by the helix-loop-helix protein Id1', Oncogene, 24, pp. 381 - 389, http://dx.doi.org/10.1038/sj.onc.1208188
Journal articles | 2004
Kus BM; Caldon CE; Andorn-Broza R; Edwards AM, 2004, 'Functional Interaction of 13 Yeast SCF Complexes with a Set of Yeast E2 Enzymes In Vitro', Proteins: Structure, Function and Genetics, 54, pp. 455 - 467, http://dx.doi.org/10.1002/prot.10620
Journal articles | 2004
Nadkarni MA; Caldon CE; Chhour KL; Fisher IP; Martin FE; Jacques NA; Hunter N, 2004, 'Carious dentine provides a habitat for a complex array of novel Prevotella-like bacteria', Journal of Clinical Microbiology, 42, pp. 5238 - 5244, http://dx.doi.org/10.1128/JCM.42.11.5238-5244.2004
Journal articles | 2003
Paramaesvaran M; Caldon E; Najdi S; Gonzaga G; Hunter N; Nguyen K; McDonald J; Langley DB; Crossley MJ; Collyer CA; Esvaran M, 2003, 'Porphyrin-mediated Cell Surface Heme Capture from Hemoglobin by Porphyromonas gingivalis.', Journal of Bacteriology, 185, pp. 2528 - 2537, http://dx.doi.org/10.1128/JB.185.8.2528-2537.2003
Phan Z; Ford C; Caldon E, 2023, DNA repair biomarkers to guide usage of combined PARP inhibitors and chemotherapy: a meta-analysis and systematic review, , http://dx.doi.org/10.1101/2023.05.24.23290442
Conference Abstracts | 2022
Freelander A; Laven-Law G; Eshraghi L; Chia KM; Pickering M; Yong A; Wilkinson A; Alexandrou S; Caldon CE; Hickey TE; Tilley WD; Lim E, 2022, 'Combination CDK4/6 inhibition and AR agonism suppresses the growth of CDK4/6 inhibitor resistant breast cancers', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, Vol. 82, http://dx.doi.org/10.1158/1538-7445.SABCS21-PD2-02
Preprints | 2020
Aziz D; Portman N; Fernandez KJ; Lee C; Alexandrou S; Llop-Guevara A; Yong A; Wilkinson A; Sergio CM; Ferraro D; Etemadmoghadam D; Bowtell D; Investigators K; Serra V; Waring P; Lim E; Caldon CE, 2020, Cyclin E1 protein is stabilized in BRCA1 mutated breast cancers leading to synergy between CDK2 and PARP inhibitors, , http://dx.doi.org/10.1101/2020.01.29.911883
Conference Abstracts | 2020
Hickey T; Selth L; Chia KM; Milioli HH; Laven-Law G; Roden D; Jindal S; Hui M; Ebrahimie E; Birrel SN; Stello S; Iggo R; Alexandrou S; Caldon L; Finlay-Shultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorious CA; Swarbrick A; Lim E; Carrol JS; Tilley WD, 2020, 'The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in Journal of the Endocrine Society, Oxford University Press (OUP), presented at Endocrine Society Annual Meeting, http://dx.doi.org/10.1210/jendso/bvaa046.982
Chia KM; Milioli HH; Portman N; Laven-Law G; Coulson R; Young A; Segara D; Parker A; Caldon L; Deng N; Swarbrick A; Tilley W; Hickey T; Lim E, 2019, 'Targeting AR in endocrine-resistant breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P012
Conference Abstracts | 2019
Lim E; Hickey TA; Selth LA; Chia KM; Milioli HH; Roden D; Laven-Law G; Jindal S; Hui M; Ebrahimie E; Birrell SN; Stelloo S; Caldon CE; Finlay-Schultz J; Abdel-Fatah TM; Ellis IO; Zwart W; Palmieri C; Sartorius CA; Swarbrick A; Carroll JS; Tilley WD, 2019, 'The androgen receptor is a tumour suppressor in estrogen receptor positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 80, presented at 42nd Annual San Antonio Breast Cancer Symposium, TX, San Antonio, 09 December 2019 - 14 December 2019, http://dx.doi.org/10.1158/1538-7445.SABCS19-GS2-03
Conference Presentations | 2019
Portman N; Milioli HH; Alexandrou S; Coulson R; Young A; Chia KM; Haup S; Haup Y; Caldon L; Lim E, 2019, 'The MDM2 inhibitor NVP-CGM097 synergises with fulvestrant and inhibits Estrogen Receptor positive breast cancer', presented at Hormone-Dependent Cancers (GRS), Newry, USA
Conference Abstracts | 2019
Portman N; Milioli HH; Young A; Coulson R; Alexandrou S; Lam N; Haup S; Haup Y; Caldon L; Deng N; Lim E, 2019, 'Activation of p53 in combination with endocrine and CDK targeted therapies in ER+ breast cancer', in Oncolabs, presented at 7th PacRim Breast & Prostate Cancer Meeting, http://dx.doi.org/10.1530/oncolabs.1.P043
Preprints | 2018
Du Q; Bert SA; Armstrong NJ; Caldon CE; Song JZ; Nair SS; Gould CM; Luu PL; Khoury A; Qu W; Zotenko E; Stirzaker C; Clark SJ, 2018, Replication timing shapes the cancer epigenome and the nature of chromosomal rearrangements, , http://dx.doi.org/10.1101/251280
Conference Abstracts | 2018
Whittle JR; Vaillant F; Policheni AN; Liu K; Pal B; Giner G; Fernandez K; Gray DH; Caldon CE; Smyth GK; Visvader JE; Lindeman GJ, 2018, 'Synergistic targeting of CDK4/6 and BCL-2 pathways in estrogen receptor positive breast cancer', in CANCER RESEARCH, AMER ASSOC CANCER RESEARCH, TX, San Antonio, Vol. 79, presented at San Antonio Breast Cancer Symposium, TX, San Antonio, 04 December 2018 - 08 December 2018, http://dx.doi.org/10.1158/1538-7445.SABCS18-PD7-07